Story · Medicine & Biotech

Jon Wigginton: FDA Complete Response Letter for Ivonescimab in Post-TKI NSCLC

1 outlet · first reported by OncoDaily on

Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “Ivonescimab BLA seeking approval in patients with locally-advanced or metastatic NSCLC post TKI rejected by FDA (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study
    Jon Wigginton: FDA Complete Response Letter for Ivonescimab in Post-TKI NSCLC

    Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “Ivonescimab BLA seeking approval in patients with locally-advanced or metastatic NSCLC post TKI rejected by FDA

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.